Global Micro-Invasive Glaucoma Implants Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Micro-Invasive Glaucoma Implants Market Segmentation, By Procedure (Trabecular Micro-Bypass Shunt, Hydrus Micro-Stent, Trabectome, Gonioscopy-Assisted Transluminal Traculomotomy, Kahook Dual Blade, Trab 360, Ab-Interno Canaloplasty, and Supraciliary Microstenting), Implant Model (Long, Thin Tube, and Large), End-User (Eye Hospitals, Opthalmology Clinics, and Outpatient Surgical Centers) - Industry Trends and Forecast to 2032

Micro-Invasive Glaucoma Implants Market Size

• The global micro-invasive glaucoma implants market size was valued at USD 413.96 million in 2024 and is expected to reach USD 3,397.67 million by 2032, at a CAGR of 30.10% during the forecast period
• The market growth for micro-invasive glaucoma implants (MIGS) is largely fueled by the rising global prevalence of glaucoma, particularly within the aging population. Technological advancements in MIGS devices, offering safer, less invasive procedures with faster recovery times and reduced complications compared to traditional glaucoma surgeries, are significantly boosting adoption
• Furthermore, increasing patient and physician demand for effective, yet less disruptive, solutions for managing intraocular pressure is establishing MIGS as a preferred modern glaucoma treatment. These converging factors are accelerating the uptake of MIGS solutions, thereby significantly boosting the industry's growth

Micro-Invasive Glaucoma Implants Market Analysis

• Micro-invasive glaucoma implants (MIGS), designed to lower intraocular pressure with minimal trauma, are becoming increasingly vital in the treatment of mild-to-moderate glaucoma due to their safety profile, shorter recovery times, and compatibility with cataract surgeries
• The rising demand for MIGS is primarily driven by the growing prevalence of glaucoma globally, increasing geriatric population, advancements in ophthalmic surgical technologies, and the preference for minimally invasive procedures by both patients and ophthalmologists
• North America dominates the micro-invasive glaucoma implants market, with the largest revenue share of 36.7% in 2024, fueled by high awareness levels, early adoption of innovative ophthalmic procedures, favorable reimbursement policies, and the presence of key industry players
• Asia-Pacific is expected to be the fastest growing region in the micro-invasive glaucoma implants market during the forecast period, with a CAGR of 9.6%, driven by increasing healthcare expenditures, rising glaucoma incidence, and expanding access to advanced eye care in countries such as India and China
• The trabecular micro-bypass stents segment dominates the MIGS market, with a market share of 65% in 2024. This dominance is attributed to their proven efficacy, ease of implantation, and strong clinical backing, making them a preferred choice among ophthalmic surgeons worldwide

Report Scope and Micro-Invasive Glaucoma Implants Market Segmentation 

Micro-Invasive Glaucoma Implants Market Trends

“Growing Demand for Minimally Invasive and Combination Procedures”

• A significant and accelerating trend in the global micro-invasive glaucoma implants market is the growing preference for minimally invasive surgical techniques, particularly those that can be performed alongside cataract surgery. This trend is enhancing patient outcomes while reducing recovery times and procedural risks

  • For instance, iStent and Hydrus Microstent are commonly used in combination with phacoemulsification procedures, allowing ophthalmologists to address both cataract and glaucoma in a single surgical session. This dual-treatment approach improves surgical efficiency and appeals to both surgeons and patients

• Minimally invasive implants offer the advantage of preserving conjunctival tissue and reducing the need for postoperative interventions. Devices such as the XEN Gel Stent and OMNI Surgical System exemplify this innovation by offering effective intraocular pressure (IOP) control through micro-incisions and simplified implantation techniques
• The demand for such implants is rising among aging populations and glaucoma patients seeking alternatives to traditional filtration surgeries, which carry higher risks and longer recovery periods. As a result, healthcare providers and surgical centers are increasingly adopting MIGS as a first-line intervention for early-to-moderate glaucoma
• This trend is also supported by favorable reimbursement policies in several developed markets, such as the United States and parts of Europe, which are encouraging wider procedural adoption. In addition, training programs and increased surgeon familiarity with MIGS techniques are accelerating market penetration
• The preference for safer, faster, and less invasive glaucoma management solutions is reshaping the treatment landscape, prompting manufacturers to invest in newer device iterations and broadening the appeal of MIGS procedures across global ophthalmic markets

Micro-Invasive Glaucoma Implants Market Dynamics

Driver

“Growing Demand Driven by Glaucoma Prevalence and Aging Population”

• The increasing global prevalence of glaucoma, particularly among the aging population, is a major driver for the growing demand for Micro-Invasive Glaucoma Implants (MIGS). As glaucoma is a leading cause of irreversible blindness, early and effective intervention is becoming a public health priority

  • For instance, according to the World Health Organization, over 76 million people were affected by glaucoma globally in 2020, a figure projected to surpass 111 million by 2040. This demographic shift is prompting ophthalmologists to seek safer, less invasive treatment options such as MIGS

• MIGS procedures offer advantages such as reduced surgical trauma, quicker recovery, and the ability to be combined with cataract surgery, making them particularly attractive for elderly patients
• Furthermore, the increasing awareness among both patients and healthcare providers about the benefits of early glaucoma management is supporting the adoption of MIGS devices in clinical practice
• Government initiatives aimed at improving access to eye care and the growing availability of trained specialists in developing markets are further contributing to market expansion. The convenience of outpatient procedures and fewer post-operative complications also appeal to patients seeking low-risk interventions for chronic eye conditions

Restraint/Challenge

“Limited Reimbursement and High Device Costs”

• Despite their clinical benefits, micro-invasive glaucoma implants face challenges related to reimbursement disparities and high procedural costs, which can hinder their adoption in certain regions

  • For instance, while the U.S. and some European countries offer partial reimbursement for MIGS procedures, many developing countries lack comprehensive insurance coverage for these devices, leading to high out-of-pocket expenses for patients

• This cost barrier becomes more pronounced when patients are required to pay for both cataract and MIGS procedures, or when newer implant technologies are not yet included in public health coverage lists
• Moreover, the cost of the devices themselves—ranging from several hundred to thousands of dollars—can be a deterrent for healthcare systems with limited budgets, especially in low- and middle-income countries
• To overcome this, industry players must work with regulatory authorities and insurance providers to establish favorable reimbursement pathways. In addition, cost-effective device innovations and localized manufacturing could help reduce pricing pressure and improve accessibility in price-sensitive markets
• Bridging these gaps will be critical for ensuring equitable access to MIGS treatments and sustaining long-term market growth

Micro-Invasive Glaucoma Implants Market Scope

The market is segmented on the basis of procedure, implant model, and end-user.

• By Procedure

On the basis of procedure, the micro-invasive glaucoma implants market is segmented into trabecular micro-bypass shunt, hydrus micro-stent, trabectome, gonioscopy-assisted transluminal trabeculotomy (GATT), Kahook Dual Blade, Trab 360, Ab-Interno canaloplasty, and supraciliary microstenting. The trabecular micro-bypass shunt segment dominated with the largest market revenue share of 65% in 2024, attributed to its strong clinical adoption, minimally invasive profile, and ability to be combined with cataract procedures. Its proven long-term IOP-lowering efficacy and safety profile drive its preference among ophthalmic surgeons.

The hydrus micro-stent segment is projected to witness the fastest growth rate of 10.5% CAGR from 2025 to 2032, driven by its innovative design for enhanced aqueous outflow and promising clinical outcomes in patients with mild-to-moderate glaucoma.

• By Implant Model

Based on implant model, the market is segmented into long, thin tube, and large implants. The thin tube model held the largest market revenue share in 2024, driven by its minimally invasive insertion technique and compatibility with ab-interno procedures. Its popularity is bolstered by reduced postoperative complications and improved patient outcomes.

The long implant model is expected to exhibit the fastest CAGR from 2025 to 2032 due to ongoing innovations aimed at enhancing aqueous humor drainage through extended channels and its growing adoption in complex glaucoma cases.

• By End-User

On the basis of end-user, the micro-invasive glaucoma implants market is segmented into eye hospitals, ophthalmology clinics, and outpatient surgical centers. The eye hospitals segment accounted for the largest market share in 2024, supported by the presence of specialized surgical teams, advanced ophthalmic equipment, and higher surgical volumes. Hospitals serve as key centers for training and adopting new glaucoma technologies.

The ophthalmology clinics segment is projected to witness the highest CAGR from 2025 to 2032, driven by increasing preference for outpatient services, cost-effective procedures, and the rising establishment of specialty eye care chains in both developed and emerging markets.

Micro-Invasive Glaucoma Implants Market Regional Analysis

• North America dominates the micro-invasive glaucoma implants market with the largest revenue share of 36.7% in 2024, driven by a rising prevalence of glaucoma, early adoption of advanced ophthalmic technologies, and strong healthcare infrastructure
• Patients and providers in the region highly value the minimally invasive nature of MIGS procedures, shorter recovery times, and their compatibility with cataract surgeries, making them a preferred treatment option for mild-to-moderate glaucoma
• This widespread adoption is further supported by favorable reimbursement policies, a high concentration of skilled ophthalmologists, and continued innovation from key industry players, establishing MIGS as a leading glaucoma management solution in the U.S. and Canada

U.S. Micro-Invasive Glaucoma Implants Market Insight

The U.S. micro-invasive glaucoma implants market captured the largest revenue share of 43.2% in 2024 within North America, fueled by a high prevalence of glaucoma, a well-established healthcare system, and rapid adoption of innovative ophthalmic devices. The growing inclination toward minimally invasive surgical options, coupled with favorable reimbursement policies, is accelerating the adoption of MIGS in clinical practice. In addition, strong support from medical associations and the early approval of advanced implants are expected to continue driving market expansion.

Europe Micro-Invasive Glaucoma Implants Market Insight

The Europe micro-invasive glaucoma implants market is projected to expand at a CAGR of 10.2% throughout the forecast period, primarily driven by a growing aging population and increased emphasis on early-stage glaucoma treatment. The region's healthcare infrastructure, combined with government support for innovative therapies, is fostering the adoption of MIGS. Countries such as Germany, the U.K., and France are witnessing increased MIGS procedures both in standalone treatments and in combination with cataract surgery.

U.K. Micro-Invasive Glaucoma Implants Market Insight

The U.K. micro-invasive glaucoma implants market is anticipated to grow at a CAGR of 10.8% during the forecast period, driven by rising awareness about glaucoma management and the push for early intervention. Surgeons and healthcare providers in the U.K. are increasingly integrating MIGS into standard glaucoma treatment due to its minimally invasive nature, favorable recovery profile, and improved patient compliance.

Germany Micro-Invasive Glaucoma Implants Market Insight

The Germany micro-invasive glaucoma implants market is expected to expand at a CAGR of 11.1% during the forecast period, fueled by advanced healthcare delivery systems and strong governmental support for innovative medical devices. The country’s focus on precision medicine and efficient surgical interventions is creating demand for MIGS devices, particularly among older patients and those undergoing combined glaucoma and cataract surgeries.

Asia-Pacific Micro-Invasive Glaucoma Implants Market Insight

The Asia-Pacific micro-invasive glaucoma implants market is poised to grow at the fastest CAGR of 9.6% during the forecast period of 2025 to 2032, driven by rapid urbanization, increasing healthcare investments, and a growing middle-class population in countries such as China, Japan, and India. The availability of cost-effective implants and rising glaucoma awareness are making MIGS more accessible across emerging economies.

Japan Micro-Invasive Glaucoma Implants Market Insight

The Japan micro-invasive glaucoma implants market is gaining momentum due to the country's advanced medical technology landscape and high demand for early-stage glaucoma management. With a rapidly aging population and increasing prevalence of open-angle glaucoma, MIGS is becoming a preferred option for ophthalmologists. The integration of these implants into routine ophthalmic surgery is supporting consistent growth across both private and public healthcare institutions.

China Micro-Invasive Glaucoma Implants Market Insight

The China micro-invasive glaucoma implants market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to robust government healthcare reforms, a surge in glaucoma cases, and expanded access to surgical care. China’s large patient pool and domestic manufacturing capabilities enable a broader range of MIGS devices to be introduced, making treatment more affordable and widely adopted across urban and semi-urban areas.

Micro-Invasive Glaucoma Implants Market Share

The micro-invasive glaucoma implants industry is primarily led by well-established companies, including:

• Alcon (Switzerland)
• Bausch + Lomb (U.S.)
• Carl Zeiss AG (Germany)
• Johnson & Johnson Services, Inc.U.S.)
• Lumenis Be Ltd. (Israel)
• Glaukos Corporation (U.S.)
• Lumibird Medical (France)
• Iridex Corporation (U.S.)
• Haag-Streit (Switzerland)
• Ziemer Ophthalmic Systems AG (Switzerland)
• Sonomed Escalon (U.S.)
• HumanOptics Holdings AG (Germany)
• EssilorLuxottica (France)
• NIDEK CO., LTD. (Japan)
• Santen Pharmaceutical Co., Ltd. (Japan)

Latest Developments in Global Micro-Invasive Glaucoma Implants Market

• In December 2023, Glaukos Corporation received FDA approval for its iDose TR, a travoprost intraocular implant developed to provide long-term reduction of intraocular pressure (IOP) in glaucoma patients. Designed for sustained drug delivery, iDose TR offers an alternative to daily eye drops, with efficacy lasting up to 36 months. This milestone reflects the growing adoption of minimally invasive, long-duration glaucoma therapies
• In September 2022, Glaukos Corporation announced a significant milestone of more than one million iStent family of technologies implanted worldwide. This achievement solidified Glaukos's position as the corporate founder and pioneer of the micro-invasive glaucoma surgery (MIGS) marketplace, reflecting decades of investment in innovative therapies for glaucoma patients
• In November 2021, iSTAR Medical received European market approval for its MINIject implant, marking a pivotal milestone in the glaucoma treatment landscape. MINIject became the only commercially available minimally invasive glaucoma surgery (MIGS) device targeting the supraciliary space, providing a new treatment pathway for open-angle glaucoma

SKU-36639